Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15317708 | 0.89 | KMT2A (0.58) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL10194849 | 0.87 | GRM3 (0.53) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL15317651 | 0.84 | KMT2A (0.61) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL15317703 | 0.84 | KMT2A (0.54) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL15317634 | 0.81 | KMT2A (0.57) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL15317650 | 0.81 | KMT2A (0.57) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL18199523 | 0.80 | L3MBTL3 (0.48) | — | |
| SCHEMBL16845219 | 0.80 | L3MBTL3 (0.48) | — | |
| SCHEMBL15317712 | 0.79 | MEN1 (0.61) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6270590 | 0.79 | HPGD (0.73) | KMT2AMEN1ALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | KMT2A 3615/4885MEN1 3827/4885ALDH1A1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.